Email updates

Keep up to date with the latest news and content from BMC Dermatology and BioMed Central.

Open Access Case report

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series

Michelle A Lowes1*, James A Turton2, James G Krueger1 and Ross StC Barnetson2

Author Affiliations

1 Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA

2 Department of Dermatology, Royal Prince Alfred Hospital, New South Wales, Australia

For all author emails, please log on.

BMC Dermatology 2005, 5:9  doi:10.1186/1471-5945-5-9

Published: 18 August 2005



Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today.

Case presentations

We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α).


These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.